SG11201501137VA - Substituted pyrazoles as n-type calcium channel blockers - Google Patents
Substituted pyrazoles as n-type calcium channel blockersInfo
- Publication number
- SG11201501137VA SG11201501137VA SG11201501137VA SG11201501137VA SG11201501137VA SG 11201501137V A SG11201501137V A SG 11201501137VA SG 11201501137V A SG11201501137V A SG 11201501137VA SG 11201501137V A SG11201501137V A SG 11201501137VA SG 11201501137V A SG11201501137V A SG 11201501137VA
- Authority
- SG
- Singapore
- Prior art keywords
- calcium channel
- channel blockers
- type calcium
- substituted pyrazoles
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683777P | 2012-08-16 | 2012-08-16 | |
| PCT/US2013/055271 WO2014028803A1 (en) | 2012-08-16 | 2013-08-16 | Substituted pyrazoles as n-type calcium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501137VA true SG11201501137VA (en) | 2015-04-29 |
Family
ID=49036655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501137VA SG11201501137VA (en) | 2012-08-16 | 2013-08-16 | Substituted pyrazoles as n-type calcium channel blockers |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8901314B2 (es) |
| EP (1) | EP2885293B1 (es) |
| JP (2) | JP2015524852A (es) |
| KR (1) | KR20150042834A (es) |
| CN (2) | CN104903316B (es) |
| AU (2) | AU2013302471B2 (es) |
| BR (1) | BR112015003395A2 (es) |
| CA (1) | CA2882123C (es) |
| CL (1) | CL2015000358A1 (es) |
| CR (1) | CR20150069A (es) |
| EA (1) | EA201590380A1 (es) |
| ES (1) | ES2600743T3 (es) |
| HK (1) | HK1214860A1 (es) |
| IL (1) | IL237191A0 (es) |
| MX (1) | MX2015002038A (es) |
| PE (1) | PE20151140A1 (es) |
| PH (1) | PH12015500315A1 (es) |
| SG (1) | SG11201501137VA (es) |
| WO (1) | WO2014028803A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015003393A2 (pt) | 2012-08-16 | 2017-07-04 | Janssen Pharmaceutica Nv | pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| AU2016277126A1 (en) | 2015-06-12 | 2017-12-14 | Vettore, LLC | MCT4 inhibitors for treating disease |
| KR101743960B1 (ko) | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
| TW201718557A (zh) * | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TW201726128A (zh) * | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
| WO2017139329A1 (en) * | 2016-02-09 | 2017-08-17 | Alexander Krantz | Site-selective functionalization of proteins using traceless affinity lables |
| KR102573333B1 (ko) | 2016-06-28 | 2023-08-31 | 삼성디스플레이 주식회사 | 표시 장치 |
| BR112019011825A2 (pt) | 2016-12-12 | 2019-10-22 | Vettore Llc | composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente |
| WO2019090242A1 (en) | 2017-11-04 | 2019-05-09 | Advanced Proteome Therapeutics Inc. | Composition and method for modifying polypeptides |
| JP6800492B2 (ja) * | 2018-06-29 | 2020-12-16 | ＭｉＺ株式会社 | 水素を含む癌性疼痛の抑制もしくは軽減のための組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| US6117841A (en) * | 1997-05-30 | 2000-09-12 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
| WO2002005799A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| WO2004033432A1 (ja) * | 2002-10-09 | 2004-04-22 | Ssp Co., Ltd. | 抗真菌活性を有する新規ピラゾール化合物 |
| BRPI0410871A (pt) * | 2003-05-30 | 2006-07-04 | Neuromed Tech Inc | 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n |
| WO2007075524A2 (en) * | 2005-12-22 | 2007-07-05 | Merck & Co., Inc. | Substituted piperidines as calcium channel blockers |
| MX2010009652A (es) * | 2008-03-11 | 2010-09-30 | Danisco Us Inc | Glucoamilasa y fitasa de buttiauxella durante la sacarificacion. |
| EP2676956A1 (en) * | 2008-08-01 | 2013-12-25 | Purdue Pharma L.P. | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof |
| KR101052065B1 (ko) * | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
-
2013
- 2013-08-16 EP EP13753391.5A patent/EP2885293B1/en active Active
- 2013-08-16 MX MX2015002038A patent/MX2015002038A/es not_active Application Discontinuation
- 2013-08-16 JP JP2015527652A patent/JP2015524852A/ja not_active Withdrawn
- 2013-08-16 SG SG11201501137VA patent/SG11201501137VA/en unknown
- 2013-08-16 CN CN201380054106.3A patent/CN104903316B/zh not_active Expired - Fee Related
- 2013-08-16 CA CA2882123A patent/CA2882123C/en not_active Expired - Fee Related
- 2013-08-16 ES ES13753391.5T patent/ES2600743T3/es active Active
- 2013-08-16 US US13/968,473 patent/US8901314B2/en active Active
- 2013-08-16 WO PCT/US2013/055271 patent/WO2014028803A1/en active Application Filing
- 2013-08-16 BR BR112015003395A patent/BR112015003395A2/pt not_active IP Right Cessation
- 2013-08-16 AU AU2013302471A patent/AU2013302471B2/en not_active Ceased
- 2013-08-16 PE PE2015000208A patent/PE20151140A1/es not_active Application Discontinuation
- 2013-08-16 EA EA201590380A patent/EA201590380A1/ru unknown
- 2013-08-16 KR KR20157006349A patent/KR20150042834A/ko not_active Application Discontinuation
- 2013-08-16 CN CN201711011681.1A patent/CN107857757A/zh active Pending
-
2015
- 2015-02-10 CR CR20150069A patent/CR20150069A/es unknown
- 2015-02-11 IL IL237191A patent/IL237191A0/en unknown
- 2015-02-13 PH PH12015500315A patent/PH12015500315A1/en unknown
- 2015-02-16 CL CL2015000358A patent/CL2015000358A1/es unknown
-
2016
- 2016-03-11 HK HK16102720.5A patent/HK1214860A1/zh unknown
-
2017
- 2017-11-16 AU AU2017261551A patent/AU2017261551B2/en not_active Ceased
- 2017-12-26 JP JP2017249223A patent/JP6294559B1/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015000358A1 (es) | 2015-06-12 |
| BR112015003395A2 (pt) | 2017-07-04 |
| HK1214860A1 (zh) | 2016-08-05 |
| US8901314B2 (en) | 2014-12-02 |
| CR20150069A (es) | 2015-05-18 |
| WO2014028803A1 (en) | 2014-02-20 |
| PH12015500315A1 (en) | 2015-03-30 |
| EP2885293B1 (en) | 2016-07-27 |
| CA2882123A1 (en) | 2014-02-20 |
| PE20151140A1 (es) | 2015-08-07 |
| CN104903316B (zh) | 2017-11-28 |
| AU2017261551B2 (en) | 2019-07-04 |
| AU2017261551A1 (en) | 2017-12-07 |
| ES2600743T3 (es) | 2017-02-10 |
| MX2015002038A (es) | 2016-01-22 |
| CA2882123C (en) | 2021-07-20 |
| KR20150042834A (ko) | 2015-04-21 |
| JP6294559B1 (ja) | 2018-03-14 |
| CN104903316A (zh) | 2015-09-09 |
| IL237191A0 (en) | 2015-04-30 |
| EP2885293A1 (en) | 2015-06-24 |
| EA201590380A1 (ru) | 2015-07-30 |
| AU2013302471B2 (en) | 2017-08-17 |
| CN107857757A (zh) | 2018-03-30 |
| US20140163031A1 (en) | 2014-06-12 |
| AU2013302471A1 (en) | 2015-02-26 |
| JP2015524852A (ja) | 2015-08-27 |
| JP2018065865A (ja) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237190A0 (en) | Pyrazoles are converted as n-type calcium channel blockers | |
| HK1217946A1 (zh) | 司普力西歐他汀類似物 | |
| IL237191A0 (en) | Pyrazoles are converted as n-type calcium channel blockers | |
| HK1248702A1 (zh) | 取代的吡咯烷-2-甲酰胺 | |
| HK1200830A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
| HK1204797A1 (en) | Novel anti-siglec15 antibody -siglec-15 | |
| HK1206724A1 (en) | Substituted benzothienopyrimidines | |
| IL237192A0 (en) | Pyrrolopyrazoles as n-type calcium channel blockers | |
| IL233059A0 (en) | Synthetic Wakanjin | |
| HK1211486A1 (en) | Novel uses | |
| EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
| HK1206022A1 (zh) | 取代的咪唑並噠嗪 | |
| HK1217690A1 (zh) | 作爲 型鈣通道阻滯劑的環戊基吡唑 | |
| IL243683A0 (en) | Imidazoles are converted as n-type calcium channel blockers | |
| PL2617907T3 (pl) | Rynna szczelinowa | |
| GB201216524D0 (en) | Project P | |
| AU347046S (en) | Sandals | |
| GB201222528D0 (en) | Novel uses | |
| GB201222391D0 (en) | Novel Uses | |
| GB201203947D0 (en) | Novel methodology | |
| GB201206268D0 (en) | Starting Line | |
| GB201214973D0 (en) | CWM extension | |
| AU348221S (en) | Calibrator | |
| AU344904S (en) | Flowerpot | |
| GB201206473D0 (en) | Sandal system |